Perspective Therapeutics Inc (CATX)

$4.41 -0.01 (-0.23%)
Market Cap 502.45M
Revenue (ttm) 880,000.00
Net Income (ttm) -103.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,718.18%
Debt to Equity Ratio 0.01
Volume 1,053,800
Avg Vol 3,963,016
Day's Range N/A - N/A
Shares Out 113.93M
Stochastic %K 76%
Beta 1.86
Analysts Strong Sell
Price Target $12.86

Company Profile

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a b...

Industry: Medical Devices
Sector: Healthcare
Phone: 206 676 0900
Address:
2401 Elliott Avenue, Suite 320, Seattle, United States
Xanderzzzzzzz
Xanderzzzzzzz Apr. 3 at 11:05 PM
$CATX
0 · Reply
JDinvestments
JDinvestments Apr. 2 at 7:02 PM
$CATX time for morty the moron to drop the hammer 🔨 🤔🤔🤔 STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂
0 · Reply
watchaddict
watchaddict Apr. 2 at 12:57 PM
$CATX Anyone else here like IMRX?
0 · Reply
ltcman
ltcman Apr. 2 at 12:28 PM
$CATX a PSA that the markets will be closed tomorrow for Good Friday.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Apr. 2 at 11:26 AM
$CATX https://perspectivetherapeutics.com/pr/perspective-therapeutics-to-participate-in-upcoming-investor-conferences
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Apr. 2 at 11:26 AM
$CATX 25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside Chat Date: Tuesday, April 14, 2026 Time: 9:30-10:10 a.m. ET Location: Virtual Piper Sandler Spring Biopharma Symposium – 1x1s only Date: Thursday, April 16, 2026 Location: Boston, MA
0 · Reply
rughead64
rughead64 Apr. 2 at 11:02 AM
$CATX investor conferences PR
0 · Reply
JDinvestments
JDinvestments Apr. 1 at 11:47 PM
$CATX https://www.tipranks.com/news/company-announcements/perspective-therapeutics-highlights-progress-in-212pb-oncology-pipeline?utm_source=webullapp.com&utm_medium=referral STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂
0 · Reply
watchaddict
watchaddict Apr. 1 at 8:48 PM
$CATX Good news we going sizzler all you can EAT
0 · Reply
ltcman
ltcman Apr. 1 at 8:31 PM
$CATX Form 8-K filed.
2 · Reply
Latest News on CATX
Perspective Therapeutics to Participate in Upcoming Investor Conferences

Apr 2, 2026, 7:00 AM EDT - 2 days ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Mar 17, 2026, 4:45 PM EDT - 18 days ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Mar 16, 2026, 4:07 PM EDT - 19 days ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Feb 17, 2026, 7:00 AM EST - 6 weeks ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Feb 2, 2026, 8:35 AM EST - 2 months ago

Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space

Jan 30, 2026, 3:37 PM EST - 2 months ago

Perspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting Space

Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 9:46 PM EST - 2 months ago

Perspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Jan 9, 2026, 7:00 AM EST - 3 months ago

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:00 AM EST - 3 months ago

Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics to Participate in Upcoming December Conferences

Nov 20, 2025, 7:00 AM EST - 4 months ago

Perspective Therapeutics to Participate in Upcoming December Conferences

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 11:11 PM EST - 5 months ago

Perspective Therapeutics, Inc. (CATX) Presents at UBS Global Healthcare Conference 2025 Transcript

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Nov 10, 2025, 4:05 PM EST - 5 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Perspective Therapeutics to Participate in Upcoming November Conferences

Oct 31, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Participate in Upcoming November Conferences

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:00 AM EDT - 5 months ago

Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Oct 20, 2025, 5:05 PM EDT - 5 months ago

Perspective Therapeutics, Inc. (CATX) Discusses Updated Interim VMT-a-NET Clinical Data Presented at ESMO Transcript

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Oct 20, 2025, 4:00 AM EDT - 5 months ago

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Sep 3, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

Perspective Therapeutics to Participate in Upcoming September Conferences

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Perspective Therapeutics to Participate in Upcoming September Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Aug 13, 2025, 6:45 AM EDT - 8 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Aug 2, 2025, 8:53 AM EDT - 8 months ago

Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Jul 24, 2025, 12:45 PM EDT - 9 months ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Jul 15, 2025, 7:00 AM EDT - 9 months ago

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Jun 21, 2025, 8:00 AM EDT - 10 months ago

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Jun 21, 2025, 8:00 AM EDT - 10 months ago

Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

May 30, 2025, 5:21 PM EDT - 11 months ago

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

May 12, 2025, 4:36 PM EDT - 11 months ago

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

May 1, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Apr 23, 2025, 12:25 PM EDT - 1 year ago

Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Apr 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Apr 11, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming April Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Mar 26, 2025, 4:10 PM EDT - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Mar 13, 2025, 2:52 PM EDT - 1 year ago

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Feb 21, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Feb 5, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 24, 2025, 7:00 AM EST - 1 year ago

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Jan 6, 2025, 8:00 AM EST - 1 year ago

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Dec 23, 2024, 11:13 AM EST - 1 year ago

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Dec 20, 2024, 4:16 PM EST - 1 year ago

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Nov 27, 2024, 7:00 AM EST - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Nov 21, 2024, 7:15 AM EST - 1 year ago

Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Nov 15, 2024, 4:08 PM EST - 1 year ago

Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics to Participate in Upcoming Investor Conferences in November

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Oct 16, 2024, 7:00 AM EDT - 1 year ago

Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Oct 11, 2024, 12:05 PM EDT - 1 year ago

Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Oct 11, 2024, 8:30 AM EDT - 1 year ago

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research

Xanderzzzzzzz
Xanderzzzzzzz Apr. 3 at 11:05 PM
$CATX
0 · Reply
JDinvestments
JDinvestments Apr. 2 at 7:02 PM
$CATX time for morty the moron to drop the hammer 🔨 🤔🤔🤔 STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂
0 · Reply
watchaddict
watchaddict Apr. 2 at 12:57 PM
$CATX Anyone else here like IMRX?
0 · Reply
ltcman
ltcman Apr. 2 at 12:28 PM
$CATX a PSA that the markets will be closed tomorrow for Good Friday.
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Apr. 2 at 11:26 AM
$CATX https://perspectivetherapeutics.com/pr/perspective-therapeutics-to-participate-in-upcoming-investor-conferences
1 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Apr. 2 at 11:26 AM
$CATX 25th Annual Needham Virtual Healthcare Conference – Presentation & Fireside Chat Date: Tuesday, April 14, 2026 Time: 9:30-10:10 a.m. ET Location: Virtual Piper Sandler Spring Biopharma Symposium – 1x1s only Date: Thursday, April 16, 2026 Location: Boston, MA
0 · Reply
rughead64
rughead64 Apr. 2 at 11:02 AM
$CATX investor conferences PR
0 · Reply
JDinvestments
JDinvestments Apr. 1 at 11:47 PM
$CATX https://www.tipranks.com/news/company-announcements/perspective-therapeutics-highlights-progress-in-212pb-oncology-pipeline?utm_source=webullapp.com&utm_medium=referral STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂
0 · Reply
watchaddict
watchaddict Apr. 1 at 8:48 PM
$CATX Good news we going sizzler all you can EAT
0 · Reply
ltcman
ltcman Apr. 1 at 8:31 PM
$CATX Form 8-K filed.
2 · Reply
watchaddict
watchaddict Apr. 1 at 8:28 PM
$CATX BE nice #Be Nice #morty #BeNiceToMorty #MortyGoesTotheMoon
0 · Reply
rughead64
rughead64 Apr. 1 at 8:25 PM
$CATX nice couple of days.
0 · Reply
Kingtan
Kingtan Apr. 1 at 8:02 PM
$CATX I know this baby , lets break 6$ next
0 · Reply
watchaddict
watchaddict Apr. 1 at 7:57 PM
$CATX 1000
0 · Reply
watchaddict
watchaddict Apr. 1 at 7:54 PM
$CATX 100
0 · Reply
JDinvestments
JDinvestments Apr. 1 at 6:50 PM
$CATX drop the hammer morty the moron STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂
0 · Reply
watchaddict
watchaddict Apr. 1 at 2:06 PM
$CATX LFG
0 · Reply
watchaddict
watchaddict Apr. 1 at 2:01 PM
$CATX 170 adding
0 · Reply
JDinvestments
JDinvestments Apr. 1 at 2:00 PM
$CATX wonder who the lucky buyer will be 🤔🤔🤔 STRONG BUYOUT 💰💰💰🚀🚀🚀🚀🚀🚀🥂🥂🥂
0 · Reply
watchaddict
watchaddict Apr. 1 at 1:31 PM
$CATX 500
0 · Reply
David_M_
David_M_ Apr. 1 at 1:29 PM
$CATX
0 · Reply
watchaddict
watchaddict Apr. 1 at 12:17 PM
$CATX Watch Addict Capital Reiterates Perspective Therapeutics stock rating at Outperform Raises Price target to 17.50$
0 · Reply